Who We Are
We are a clinical-stage biopharmaceutical company leveraging our proprietary non-viral gene engineering technologies to create ground-breaking, life-saving cell and gene therapies.
Our broad genetic engineering platform technologies are advancing potentially better and safer treatments to patients with serious diseases — blood cancers like multiple myeloma, solid tumor cancers like breast and ovarian cancer, and rare genetic diseases in the liver.
The organization is comprised of passionate, innovative, and nimble, results-oriented people driven by science to develop better options for patients with cancer and genetic diseases.
Mark J. Gergen
Chief Executive Officer and Chairman
Kristin Yarema, Ph.D.
President, Cell Therapy
President, Gene Therapy
Johanna Mylet, C.P.A.
Chief Financial Officer
Devon J. Shedlock, Ph.D.
Chief Scientific Officer, Cell Therapy
Chief People and Administration Officer
Harry J. Leonhardt, Esq.
General Counsel, Chief Compliance Officer, and Corporate Secretary
Senior Vice President, Regulatory Affairs
Senior Vice President, Global Operations
Senior Vice President, Business Development
Jeffrey W. Winkelman, Ph.D., J.D.
Senior Vice President, Chief Patent Counsel